Episode 25: Four Things We Are Watching For On Teva

12/07/17 • 18 min

The S&P Pharma Guy, Arthur Wong details four things S&P is watching for on Teva over the next three quarters that would help determine whether the ratings stay investment grade.

The S&P Pharma Guy, Arthur Wong details four things S&P is watching for on Teva over the next three quarters that would help determine whether the ratings stay investment grade.

Previous Episode

Episode 24: Et Tu Amazon? Amazon and Impact on Pharma Pricing

S&P Global Ratings analyst Arthur Wong takes an early look as to what a possible entry of Amazon.com Inc. into the pharma ecosystem may mean to drug pricing for generic and branded pharma. Warning: More questions than answers at this point.

Next Episode

Episode 26: Generic Drug Pricing - When Does the Pain Stop?

The S&P Pharma Guy, Arthur Wong, shares why generic drug pricing in the U.S., which has been under increasing pressure, should begin to stabilize in 2018. However, the U.S. generic drug environment will likely remain challenging over the near term and S&P harbors longer-term concerns on the industry.